T1	Participants 109 126	in ovarian cancer
T2	Participants 350 378	Patients with stage IC-IV OC
T3	Participants 884 911	PD or death in 636 patients
T4	Participants 1045 1246	Randomized induction therapy was received by 820 of 919 patients enrolled; 352 patients with CR received paclitaxel consolidation whereas 155 patients without CR received single-agent crossover therapy
